Goligorsky Michael S
Department of Medicine, Department of Pharmacology, and Department of Physiology, Renal Research Institute, New York Medical College, Valhalla, NY.
Semin Nephrol. 2014 Jul;34(4):365-73. doi: 10.1016/j.semnephrol.2014.06.003. Epub 2014 Jun 13.
Discovered more than 15 years ago, endothelial progenitor cells attract both basic and translational researchers. It has become clear that they represent a heterogeneous population of endothelial colony-forming cells, early or late outgrowth endothelial cells, or blood outgrowth endothelial cells, each characterized by differing proliferative and regenerative capacity. Scattered within the vascular wall, these cells participate in angiogenesis and vasculogenesis and support regeneration of epithelial cells. There is growing evidence that this cell population is impaired during the course of chronic cardiovascular and kidney disease when it undergoes premature senescence and loss of specialized functions. Senescence-associated secretory products released by such cells can affect the neighboring cells and further exacerbate their regenerative capacity. For these reasons, adoptive transfer of endothelial progenitor cells is being used in more than 150 ongoing clinical trials of diverse cardiovascular diseases. Attempts to rejuvenate this cell population either ex vivo or in situ are emerging. The progress in this field is paramount to regenerate the injured kidney.
内皮祖细胞在15年多以前就被发现了，它吸引了基础研究和转化研究领域的科研人员。目前已经明确，它们代表了一群异质性的内皮集落形成细胞、早期或晚期迁移内皮细胞或血源内皮细胞，每种细胞都具有不同的增殖和再生能力。这些细胞散布在血管壁内，参与血管生成和血管发生，并支持上皮细胞的再生。越来越多的证据表明，在慢性心血管疾病和肾脏疾病过程中，当这群细胞过早衰老并丧失特定功能时，其功能会受到损害。这些细胞释放的衰老相关分泌产物会影响邻近细胞，并进一步加剧其再生能力。出于这些原因，内皮祖细胞的过继转移正在超过150项正在进行的各种心血管疾病临床试验中得到应用。在体外或原位使这群细胞恢复活力的尝试正在出现。该领域的进展对于损伤肾脏的再生至关重要。
